[144] Krystal Biotech, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 Overview: Krystal Biotech, Inc. (ticker KRYS) has filed a Form 144 indicating the proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on or about 9 July 2025 on Nasdaq.

Key details

• Aggregate market value: US$3,583,375.
• Outstanding shares: 28,898,680.
• Percentage of float: roughly 0.09 % of shares outstanding.
• Seller’s position: Shares were acquired on 31 Mar 2017 as founders shares; no prior sales reported in the past three months.

The filing is a routine notice required under Rule 144 when an affiliate or insider intends to dispose of restricted or control securities. At <0.1 % of the company’s outstanding stock, the transaction is immaterial in scale and unlikely to meaningfully impact liquidity or corporate control. Nonetheless, insider sales can attract investor attention because they may be interpreted—rightly or wrongly—as signals about management’s outlook. The seller affirms they possess no undisclosed material adverse information, and no 10b5-1 trading plan adoption date is disclosed.

Investment view: This appears to be a low-impact, discretionary sale by an insider. Investors typically monitor cumulative insider activity and sale frequency rather than isolated filings of this size. No information in the document suggests operational, financial, or strategic changes at Krystal Biotech.

Positive

• Regulatory transparency: Filing demonstrates the insider is following Rule 144 disclosure requirements, supporting good governance.

Negative

• Insider selling signal: Even a small discretionary sale can be perceived negatively by some investors monitoring management sentiment.

Insights

Securities Analyst

TL;DR Routine Form 144 for 25 k shares (0.09 % float); insignificant on valuation, mildly negative sentiment due to insider selling.

From a capital-markets perspective, the proposed sale represents less than 0.1 % of the 28.9 million shares outstanding—far below any threshold likely to pressure daily trading volumes. The US$3.6 million notional value is modest for a company with a multi-billion-dollar market cap, implying negligible dilution or liquidity concerns. While insider sales often trigger knee-jerk reactions, the lack of accompanying operational disclosures, combined with the founders shares origin, suggests personal liquidity rather than strategic repositioning. I classify the filing as not impactful to earnings outlook or valuation multiples.

Corporate Governance Expert

TL;DR Governance risk minimal; standard Rule 144 compliance, no aggregation issues, no recent insider sales.

The filer certifies absence of undisclosed adverse information and reports no sales in the preceding three months, satisfying Rule 144(e) aggregation limits. There is no indication of a 10b5-1 plan, so timing is discretionary but still permissible. Given the fractional share percentage, board-level governance implications are negligible. Investors should continue to track overall insider activity trends, but this single notice does not alter governance risk assessments.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	3583375.00	28898680	07/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/31/2017	Founders Shares	Issuer			25000	03/31/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Krystal Biotech (KRYS) shares are being sold under this Form 144?

The notice covers 25,000 common shares.

What is the market value of the proposed KRYS share sale?

The aggregate market value is US$3,583,375.

What percentage of Krystal Biotech’s outstanding shares does 25,000 represent?

Approximately 0.09 % of the 28,898,680 shares outstanding.

When is the KRYS insider planning to sell the shares?

The approximate sale date stated is 09 July 2025.

Which broker will handle the KRYS share sale?

The broker is Morgan Stanley Smith Barney LLC.

Were any other KRYS shares sold by this insider in the last three months?

No. The filing states “Nothing to Report” for prior three-month sales.